

1. Benyamina, A. & Reynaud, M. [Therapeutic use of cannabis derivatives]. *Rev Prat* **64**, 165-168 (2014).
2. Feng, C. C. et al. Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats. *Pain* (2014).
3. Straub, R. H. TRPV1, TRPA1, and TRPM8 channels in inflammation, energy redirection, and water retention: role in chronic inflammatory diseases with an evolutionary perspective. *J Mol Med (Berl)* (2014).
4. Brunt, T. M., van Genugten, M., Honer-Snoeken, K., van de Velde, M. J. & Niesink, R. J. Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis. *J Clin Psychopharmacol* **34**, 344-349 (2014).
5. Webb, C. W. & Webb, S. M. Therapeutic benefits of cannabis: a patient survey. *Hawaii J Med Public Health* **73**, 109-111 (2014).
6. Wilson-Poe, A. R., Lau, B. K. & Vaughan, C. W. Repeated morphine treatment alters cannabinoid modulation of GABAergic synaptic transmission within the rat periaqueductal grey. *Br J Pharmacol* (2014).
7. Toniolo, E. F. et al. Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats. *Peptides* (2014).
8. Hama, A. T. et al. Fatty Acid Amide Hydrolase (FAAH) Inhibitors Exert Pharmacological Effects, but Lack Antinociceptive Efficacy in Rats with Neuropathic Spinal Cord Injury Pain. *PLoS One* **9**, e96396 (2014).
9. Naftali, T., Mechulam, R., Lev, L. B. & Konikoff, F. M. Cannabis for inflammatory bowel disease. *Dig Dis* **32**, 468-474 (2014).
10. Petrenko, A. B., Yamazaki, M., Sakimura, K., Kano, M. & Baba, H. Augmented tonic pain-related behavior in knockout mice lacking monoacylglycerol lipase, a major degrading enzyme for the endocannabinoid 2-arachidonoylglycerol. *Behav Brain Res* (2014).
11. Robson, P. J. Therapeutic potential of cannabinoid medicines. *Drug Test Anal* (2013).
12. Zogopoulos, P., Vasileiou, I., Patsouris, E. & Theocharis, S. E. The role of endocannabinoids in pain modulation. *Fundam Clin Pharmacol* (2013).
13. Hazekamp, A. & Heerdink, E. R. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. *Eur J Clin Pharmacol* (2013).
14. Pellkofer, H. L. et al. The Major Brain Endocannabinoid 2-AG Controls Neuropathic Pain and Mechanical Hyperalgesia in Patients with Neuromyelitis Optica. *PLoS One* **8**, e71500 (2013).
15. Fine, P. G. & Rosenfeld, M. J. The endocannabinoid system, cannabinoids, and pain. *Rambam Maimonides Med J* **4**, e0022 (2013).
16. Klauke, A. L. et al. The cannabinoid CB receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. *Eur Neuropsychopharmacol* (2013).
17. Selley, D. E., Welch, S. P. & Sim-Selley, L. J. Sphingosine lysolipids in the CNS: Endogenous cannabinoid antagonists or a parallel pain modulatory system? *Life Sci* (2013).
18. Fichna, J. et al. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty

- acid amides. *Neurogastroenterol Motil* (2013).
19. Kinsey, S. G. et al. Repeated Low Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects. *J Pharmacol Exp Ther* (2013).
 20. Otrubova, K. et al. Rational design of Fatty Acid amide hydrolase inhibitors that act by covalently bonding to two active site residues. *J Am Chem Soc* **135**, 6289-6299 (2013).
 21. Zhang, L. P., Ma, F., Abshire, S. M. & Westlund, K. N. Prolonged High Fat / Alcohol Exposure Increases TRPV4 and Its Functional Responses in Pancreatic Stellate Cells. *Am J Physiol Regul Integr Comp Physiol* (2013).
 22. Starowicz, K. et al. Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism. *PLoS One* **8**, e60040 (2013).
 23. Maione, S., Costa, B. & Di Marzo, V. Endocannabinoids: A unique opportunity to develop multitarget analgesics. *Pain* (2013).
 24. Burston, J. J. & Woodhams, S. G. Endocannabinoid system and pain: an introduction. *Proc Nutr Soc* 1-12 (2013).
 25. Ward, S. J., McAllister, S. D., Neelakantan, H. & Walker, E. A. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. *Br J Pharmacol* (2013).
 26. Macri, S. et al. Behavioral Responses to Acute and Sub-chronic Administration of the Synthetic Cannabinoid JWH-018 in Adult Mice Prenatally Exposed to Corticosterone. *Neurotox Res* (2013).
 27. Bishay, P. et al. Anandamide deficiency and heightened neuropathic pain in aged mice. *Neuropharmacology* (2013).
 28. Anderson, W. B., Gould, M. J., Torres, R. D., Mitchell, V. A. & Vaughan, C. W. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model. *Neuropharmacology* (2013).
 29. Mulvihill, M. M. & Nomura, D. K. Therapeutic Potential of Monoacylglycerol Lipase Inhibitors. *Life Sci* (2012).
 30. Caprioli, A. et al. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. *J Pharmacol Exp Ther* (2012).
 31. Chicca, A., Marazzi, J. & Gertsch, J. The antinociceptive triterpene beta-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting CB receptors. *Br J Pharmacol* (2012).
 32. Serpell, M. G., Notcutt, W. & Collin, C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. *J Neurol* (2012).
 33. Sasso, O. et al. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. *Pharmacol Res* (2012).
 34. Schreiber, A. K., Neufeld, M., Jesus, C. H. & Cunha, J. M. Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats. *Neuropharmacology* (2012).
 35. Starowicz, K. & Przewlocka, B. Modulation of neuropathic-pain-related behaviour

- by the spinal endocannabinoid/endovanilloid system. *Philos Trans R Soc Lond B Biol Sci* **367**, 3286-3299 (2012).
36. Skaper, S. D. & Facci, L. Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. *Philos Trans R Soc Lond B Biol Sci* **367**, 3312-3325 (2012).
 37. Okine, B. N. et al. Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. *Br J Pharmacol* (2012).
 38. Wilkerson, J. L. et al. Intrathecal cannabidiol CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. *Pain* (2012).
 39. Roques, B. P., Fournie-Zaluski, M. C. & Wurm, M. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. *Nat Rev Drug Discov* **11**, 292-310 (2012).
 40. Whistler, J. L. Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: From a symposium on new concepts in mu-opioid pharmacology. *Drug Alcohol Depend* (2012).
 41. Petrovski, Z., Kovacs, G., Tomboly, C., Benedek, G. & Horvath, G. Effects of Peptide and Lipid Endocannabinoids on Arthritic Pain at Spinal Level. *Anesth Analg* (2012).
 42. Rani Sagar, D., Burston, J. J., Woodhams, S. G. & Chapman, V. Dynamic changes to the endocannabinoid system in models of chronic pain. *Philos Trans R Soc Lond B Biol Sci* **367**, 3300-3311 (2012).
 43. Palazzo, E. et al. Changes in Cannabinoid Receptor Subtype 1 Activity and Interaction with Metabotropic Glutamate Subtype 5 Receptors in the Periaqueductal Gray-Rostral Ventromedial Medulla Pathway in a Rodent Neuropathic Pain Model. *CNS Neurol Disord Drug Targets* (2012).
 44. Lucas, P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. *J Psychoactive Drugs* **44**, 125-133 (2012).
 45. Xiong, W. et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors. *J Exp Med* **209**, 1121-1134 (2012).
 46. Johnson, J. R., Lossignol, D., Burnell-Nugent, M. & Fallon, M. T. An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics. *J Pain Symptom Manage* (2012).
 47. Perrotta, A. et al. Acute Reduction of Anandamide-Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medication-Overuse Headache Subjects After Withdrawal Treatment. *Headache* (2012).
 48. Stadel, R., Ahn, K. H. & Kendall, D. A. The Cannabinoid Type-1 Receptor Carboxyl-Terminus, More Than Just a Tail. *J Neurochem* (2011).
 49. de Novellis, V. et al. The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats. *Mol Pain* **7**, 7 (2011).
 50. Knerlich-Lukoschus, F. et al. Spinal Cord Injuries Induce Changes of CB1 Cannabinoid Receptor and C-C Chemokine Expression in Brain Areas Underlying Circuitry of Chronic Pain Conditions. *J Neurotrauma* (2011).

51. Heltsley, R. et al. Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. *J Anal Toxicol* **35**, 529-540 (2011).
52. De Petrocellis, L. et al. N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. *Pharmacol Res* (2011).
53. Yevenes, G. E. & Zeilhofer, H. U. Molecular sites for the positive allosteric modulation of glycine receptors by endocannabinoids. *PLoS One* **6**, e23886 (2011).
54. Clark, P. A., Capuzzi, K. & Fick, C. Medical marijuana: Medical necessity versus political agenda. *Med Sci Monit* **17**, RA249-RA261 (2011).
55. Davison, S. N. & Davison, J. S. Is There a Legitimate Role for the Therapeutic Use of Cannabinoids for Symptom Management in Chronic Kidney Disease? *J Pain Symptom Manage* (2011).
56. Ghafouri, N. et al. High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. *PLoS One* **6**, e27257 (2011).
57. Kinsey, S. G., Naidu, P. S., Cravatt, B. F., Dudley, D. T. & Lichtman, A. H. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. *Pharmacol Biochem Behav* (2011).
58. Moaddel, R. et al. Development and Characterization of Immobilized Cannabinoid Receptor (CB1/CB2) Open Tubular Column for On-line Screening. *Anal Biochem* (2011).
59. McHugh, D., Page, J., Dunn, E. & Bradshaw, H. B. Delta(9) -THC and N-arachidonyl glycine are full agonists at GPR18 and cause migration in the human endometrial cell line, HEC-1B. *Br J Pharmacol* (2011).
60. Ware, M. A. Clearing the smoke around medical marijuana. *Clin Pharmacol Ther* **90**, 769-771 (2011).
61. Galli, J. A., Sawaya, R. A. & Friedenberg, F. K. Cannabinoid Hyperemesis Syndrome. *Curr Drug Abuse Rev* (2011).
62. Gijssen, H. J. et al. 5-Sulfonyl-benzimidazoles as selective CB2 agonists-Part 2. *Bioorg Med Chem Lett* (2011).
63. Huang, J. Y., Fang, M., Li, Y. J., Ma, Y. Q. & Cai, X. H. [Analgesic effect of Corydalis yanhusuo in a rat model of trigeminal neuropathic pain.]. *Nan Fang Yi Ke Da Xue Xue Bao* **41**, 378-382 (2010).
64. Madden, M. E. & Shapiro, S. L. The Methadone Epidemic: Methadone-Related Deaths on the Rise in Vermont. *Am J Forensic Med Pathol* (2010).
65. Ware, M. A., Fitzcharles, M. A., Joseph, L. & Shir, Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. *Anesth Analg* **110**, 604-610 (2010).
66. Rivers, J. R. & Ashton, J. C. The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies. *Cent Nerv Syst Agents Med Chem* **10**, 47-64 (2010).
67. Kinsey, S. G. et al. The CB(2) cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. *Neuropharmacology* (2010).
68. Yang, S. W. et al. Structure-activity relationships of 2,4-diphenyl-1H-imidazole

- analogs as CB2 receptor agonists for the treatment of chronic pain. *Bioorg Med Chem Lett* (2010).
69. Ware, M. A. et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ* **182**, E694-E701 (2010).
 70. Pattipati, S. N., Kinsey, S. G., Guo, T., Cravatt, B. F. & Lichtman, A. H. Regulation of Inflammatory Pain by Inhibition of Fatty Acid Amide Hydrolase (FAAH). *J Pharmacol Exp Ther* (2010).
 71. Bishay, P. et al. R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. *PLoS One* **5**, e10628 (2010).
 72. McDougall, J. J. Peripheral analgesia: Hitting pain where it hurts. *Biochim Biophys Acta* (2010).
 73. Chanda, P. et al. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. *Mol Pharmacol* (2010).
 74. Pesce, A. et al. Marijuana correlates with use of other illicit drugs in a pain patient population. *Pain Physician* **13**, 283-287 (2010).
 75. Foadi, N. et al. Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids. *Naunyn Schmiedebergs Arch Pharmacol* (2010).
 76. Kinsey, S. G., Long, J. Z., Cravatt, B. F. & Lichtman, A. H. Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Inhibitors Produce Anti-Allodynic Effects in Mice Through Distinct Cannabinoid Receptor Mechanisms. *J Pain* (2010).
 77. Ablin, J. N. & Buskila, D. Emerging therapies for fibromyalgia: an update. *Expert Opin Emerg Drugs* (2010).
 78. Hoot, M. R. et al. Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice. *Brain Res* (2010).
 79. Toth, C. C., Jedrzejewski, N. M., Ellis, C. L. & Frey, W. H. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. *Mol Pain* **6**, 16 (2010).
 80. Paudel, K. S., Hammell, D. C., Agu, R. U., Valiveti, S. & Stinchcomb, A. L. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. *Drug Dev Ind Pharm* **36**, 1088-1097 (2010).
 81. Leconte, M. et al. Antiproliferative Effects of Cannabinoid Agonists on Deep Infiltrating Endometriosis. *Am J Pathol* (2010).
 82. Yu, X. H. et al. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. *Pain* (2010).
 83. Luongo, L. et al. 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2- c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. *Neurobiol Dis* **37**, 177-185 (2010).
 84. Beltramo, M. [The cannabinoid system and pain: towards new drugs?]. *J Soc Biol* **203**, 99-106 (2009).
 85. Elikottil, J., Gupta, P. & Gupta, K. The analgesic potential of cannabinoids. *J Opioid Manag* **5**, 341-357 (2009).
 86. Hornby, A. P., Sharma, M. & Stegman, B. Standardized natural product cannabis in pain management and observations at a Canadian compassion society: a case report. *Cases J* **2**, 7487 (2009).

87. Pernia-Andrade, A. J. et al. Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. *Science* **325**, 760-764 (2009).
88. Ahrens, J. et al. Positive allosteric modulatory effects of ajulemic acid at strychnine-sensitive glycine alpha1- and alpha1beta-receptors. *Naunyn Schmiedebergs Arch Pharmacol* **379**, 371-378 (2009).
89. Johnson, J. R. et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable Cancer-Related Pain. *J Pain Symptom Manage* (2009).
90. Kress, M. & Kuner, R. Mode of action of cannabinoids on nociceptive nerve endings. *Exp Brain Res* (2009).
91. Guasti, L. et al. Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. *Mol Pain* **5**, 35 (2009).
92. Sanchez Freire, V. et al. MicroRNAs May Mediate the Down-Regulation of Neurokinin-1 Receptor in Chronic Bladder Pain Syndrome. *Am J Pathol* (2009).
93. Aggarwal, S. K. et al. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. *J Opioid Manag* **5**, 153-168 (2009).
94. Lever, I. J. et al. Localization of the endocannabinoid-degrading enzyme fatty acid amide hydrolase in rat dorsal root ganglion cells and its regulation after peripheral nerve injury. *J Neurosci* **29**, 3766-3780 (2009).
95. Welch, S. P. Interaction of the cannabinoid and opioid systems in the modulation of nociception. *Int Rev Psychiatry* **21**, 143-151 (2009).
96. Garzon, J., de la Torre-Madrid, E., Rodriguez-Munoz, M., Vicente-Sanchez, A. & Sanchez-Blazquez, P. Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine. *Mol Pain* **5**, 11 (2009).
97. Kaufmann, I. et al. Enhanced Anandamide Plasma Levels in Patients with Complex Regional Pain Syndrome following Traumatic Injury: A Preliminary Report. *Eur Surg Res* **43**, 325-329 (2009).
98. Chen, L. et al. Endogenous Anandamide and Cannabinoid Receptor-2 Contribute to Electroacupuncture Analgesia in Rats. *J Pain* (2009).
99. Farquhar-Smith, W. P. Do cannabinoids have a role in cancer pain management? *Curr Opin Support Palliat Care* **3**, 7-13 (2009).
100. Markt, P. et al. Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. *J Med Chem* **52**, 369-378 (2009).
101. Tegeder, I. & Lotsch, J. Current evidence for a modulation of low back pain by human genetic variants. *J Cell Mol Med* (2009).
102. Attal, N., Mazaltarine, G., Perrouin-Verbe, B. & Albert, T. Chronic neuropathic pain management in spinal cord injury patients. What is the efficacy of pharmacological treatments with a general mode of administration? (oral, transdermal, intravenous). *Ann Phys Rehabil Med* **52**, 124-141 (2009).
103. Rahn, E. J. & Hohmann, A. G. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. *Neurotherapeutics* **6**, 713-737 (2009).
104. Bushlin, I., Rozenfeld, R. & Devi, L. A. Cannabinoid-opioid interactions during neuropathic pain and analgesia. *Curr Opin Pharmacol* (2009).

105. Kinsey, S. G. et al. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. *J Pharmacol Exp Ther* (2009).
106. Luongo, L. et al. 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2- c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. *Neurobiol Dis* (2009).
107. Cone, E. J., Caplan, Y. H., Black, D. L., Robert, T. & Moser, F. Urine drug testing of chronic pain patients: licit and illicit drug patterns. *J Anal Toxicol* **32**, 530-543 (2008).
108. Lynch, M. E. The pharmacotherapy of chronic pain. *Rheum Dis Clin North Am* **34**, 369-385 (2008).
109. Costa, B., Comelli, F., Bettoni, I., Colleoni, M. & Giagnoni, G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. *Pain* (2008).
110. Loria, F. et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. *Eur J Neurosci* (2008).
111. Romero-Sandoval, A., Nutile-McMenemy, N. & DeLeo, J. A. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. *Anesthesiology* **108**, 722-734 (2008).
112. Kerr, J. R. et al. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. *J Clin Pathol* **61**, 730-739 (2008).
113. Baastrup, C. & Finnerup, N. B. Pharmacological management of neuropathic pain following spinal cord injury. *CNS Drugs* **22**, 455-475 (2008).
114. Narang, S. et al. Patients with chronic pain on opioid therapy taking dronabinol: incidence of false negatives using radioimmunoassay. *J Opioid Manag* **4**, 21-26 (2008).
115. Haroutiunian, S., Rosen, G., Shouval, R. & Davidson, E. Open-Label, Add-on Study of Tetrahydrocannabinol for Chronic Nonmalignant Pain. *J Pain Palliat Care Pharmacother* **22**, 213-217 (2008).
116. Kraft, B. et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. *Anesthesiology* **109**, 101-110 (2008).
117. Palmer, J. A., Higuera, E. S., Chang, L. & Chaplan, S. R. Fatty Acid Amide Hydrolase Inhibition Enhances the Anti-allodynic Actions of Endocannabinoids in a Model of Acute Pain Adapted for the Mouse. *Neuroscience* (2008).
118. Narang, S. et al. Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. *J Pain* **9**, 254-264 (2008).
119. Cupini, L. M. et al. Degradation of endocannabinoids in chronic migraine and medication overuse headache. *Neurobiol Dis* (2008).
120. Williams, J., Haller, V. L., Stevens, D. L. & Welch, S. P. Decreased basal endogenous opioid levels in diabetic rodents: Effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. *Eur J Pharmacol* (2008).

121. Pollmann, W. & Feneberg, W. Current management of pain associated with multiple sclerosis. *CNS Drugs* **22**, 291-324 (2008).
122. Suplita, R. L., Eisenstein, S. A., Neely, M. H., Moise, A. M. & Hohmann, A. G. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. *Neuropharmacology* **54**, 161-171 (2008).
123. Frank, B., Serpell, M. G., Hughes, J., Matthews, J. N. & Kapur, D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. *BMJ* **336**, 199-201 (2008).
124. Ashton, J. C. & Milligan, E. D. Cannabinoids for the treatment of neuropathic pain: Clinical evidence. *Curr Opin Investig Drugs* **9**, 65-75 (2008).
125. Cohen, S. P. Cannabinoids for chronic pain. *BMJ* (2008).
126. Anand, U. et al. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. *Pain* (2008).
127. Merriam, F. V., Wang, Z. Y., Guerios, S. D. & Bjorling, D. E. Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. *Neurosci Lett* (2008).
128. Comelli, F., Giagnoni, G., Bettoni, I., Colleoni, M. & Costa, B. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. *Phytother Res* (2008).
129. Gertsch, J. Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action? *Commun Integr Biol* **1**, 26-28 (2008).
130. Kaufmann, I. et al. Anandamide and neutrophil function in patients with fibromyalgia. *Psychoneuroendocrinology* **33**, 676-685 (2008).
131. Kaufmann, I. et al. Anandamide and neutrophil function in patients with fibromyalgia. *Psychoneuroendocrinology* (2008).
132. La Rana, G. et al. AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: Role for cannabinoid receptors. *Neuropharmacology* **54**, 521-529 (2008).
133. Toth, C. & Au, S. A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy. *Pain* (2008).
134. Klein, T. W. & Newton, C. A. Therapeutic potential of cannabinoid-based drugs. *Adv Exp Med Biol* **601**, 395-413 (2007).
135. Liang, Y. C., Huang, C. C. & Hsu, K. S. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. *Neuropharmacology* (2007).
136. Whiteside, G. T., Lee, G. P. & Valenzano, K. J. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. *Curr Med Chem* **14**, 917-936 (2007).
137. Russo, R. et al. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. *J Pharmacol Exp Ther* **322**, 236-242 (2007).
138. Wallace, V. C. et al. The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. *Br J*

Pharmacol (2007).

139. Cox, M. L., Haller, V. L. & Welch, S. P. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. *Eur J Pharmacol* **570**, 50-56 (2007).
140. Cox, M. L., Haller, V. L. & Welch, S. P. Synergy between Delta(9)-tetrahydrocannabinol and morphine in the arthritic rat. *Eur J Pharmacol* (2007).
141. Smith, P. F. Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. *Expert Rev Neurother* **7**, 1157-1163 (2007).
142. Degenhardt, B. F. et al. Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study. *J Am Osteopath Assoc* **107**, 387-400 (2007).
143. Beaulieu, P. & Ware, M. Reassessment of the role of cannabinoids in the management of pain. *Curr Opin Anaesthesiol* **20**, 473-477 (2007).
144. Moulin, D. E. et al. Pharmacological management of chronic neuropathic pain -- Consensus statement and guidelines from the Canadian Pain Society. *Pain Res Manag* **12**, 13-21 (2007).
145. Dziadulewicz, E. K. et al. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: A Potent, Orally Bioavailable Human CB(1)/CB(2) Dual Agonist with Antihyperalgesic Properties and Restricted Central Nervous System Penetration. *J Med Chem* (2007).
146. Seamon, M. J., Fass, J. A., Maniscalco-Feichtl, M. & Abu-Shraie, N. A. Medical marijuana and the developing role of the pharmacist. *Am J Health Syst Pharm* **64**, 1037-1044 (2007).
147. Jensen, T. S. & Finnerup, N. B. Management of neuropathic pain. *Curr Opin Support Palliat Care* **1**, 126-131 (2007).
148. Kaufmann, I. et al. Lymphocyte subsets and the role of TH1/TH2 balance in stressed chronic pain patients. *Neuroimmunomodulation* **14**, 272-280 (2007).
149. Camilleri, M. et al. Genetic Variation in Endocannabinoid Metabolism, Gastrointestinal Motility and Sensation. *Am J Physiol Gastrointest Liver Physiol* (2007).
150. Di Marzo, V. & Petrosino, S. Endocannabinoids and the regulation of their levels in health and disease. *Curr Opin Lipidol* **18**, 129-140 (2007).
151. Petrosino, S. et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. *Neuropharmacology* **52**, 415-422 (2007).
152. Lotersztajn, S. et al. CB2 receptors as new therapeutic targets for liver diseases. *Br J Pharmacol* (2007).
153. Niehaus, J. L. et al. CB1 cannabinoid receptor activity is modulated by the interacting protein CRIP1a. *Mol Pharmacol* (2007).
154. Scully, C. Cannabis; adverse effects from an oromucosal spray. *Br Dent J* **203**, E12; discussion 336-E12; discussion 337 (2007).
155. Russo, E. B., Guy, G. W. & Robson, P. J. Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex((R)), a Cannabis-Based Medicine. *Chem Biodivers* **4**, 1729-1743 (2007).
156. Abrams, D. I. et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology* **68**, 515-521 (2007).
157. Jhaveri, M. D., Sagar, D. R., Elmes, S. J., Kendall, D. A. & Chapman, V. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and

- chronic pain. *Mol Neurobiol* **36**, 26-35 (2007).
158. Maione, S. et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. *Br J Pharmacol S* (2007).
 159. Brand, H. S. Adverse effects from a cannabis spray. *Br Dent J* **203**, 336-337 (2007).
 160. Gutierrez, T., Farthing, J. N., Zvonok, A. M., Makriyannis, A. & Hohmann, A. G. Activation of peripheral cannabinoid CB(1) and CB(2) receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. *Br J Pharmacol S* **150**, 153-163 (2007).
 161. Manzanares, J., Julian, M. & Carrascosa, A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. *Curr Neuropharmacol* **4**, 239-257 (2006).
 162. Piomelli, D. et al. Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597). *CNS Drug Rev* **12**, 21-38 (2006).
 163. Palazzo, E. et al. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. *Eur J Neurosci* **24**, 2011-2020 (2006).
 164. La Rana, G. et al. Modulation of Neuropathic and Inflammatory Pain by the Endocannabinoid Transport Inhibitor AM404 [N-(4-Hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. *J Pharmacol Exp Ther* **317**, 1365-1371 (2006).
 165. Wissel, J. et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : A double-blind placebo-controlled cross-over trial. *J Neurol* (2006).
 166. Paus, R., Schmelz, M., Biro, T. & Steinhoff, M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. *J Clin Invest* **116**, 1174-1186 (2006).
 167. Berlach, D. M., Shir, Y. & Ware, M. A. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. *Pain Med* **7**, 25-29 (2006).
 168. Ware, M. A., Ducruet, T. & Robinson, A. R. Evaluation of herbal cannabis characteristics by medical users: a randomized trial. *Harm Reduct J* **3**, 32 (2006).
 169. Sarchielli, P. et al. Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure. *Neuropsychopharmacology* (2006).
 170. Liu, C. & Walker, J. M. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. *J Neurophysiol* **96**, 2984-2994 (2006).
 171. Choong, K. C., Su, X. & Urban, M. O. Effect of CP55,940 on mechanosensory spinal neurons following chronic inflammation. *Neurosci Lett S* (2006).
 172. Schley, M. et al. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. *Curr Med Res Opin* **22**, 1269-1276 (2006).
 173. Perez, J. Combined cannabinoid therapy via an oromucosal spray. *Drugs Today (Barc)* **42**, 495-503 (2006).
 174. Petrosino, S. et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. *Neuropharmacology* (2006).
 175. Burns, T. L. & Ineck, J. R. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. *Ann Pharmacother* **40**, 251-260 (2006).

176. Bucherelli, C., Baldi, E., Mariottini, C., Passani, M. B. & Blandina, P. Aversive memory reactivation engages in the amygdala only some neurotransmitters involved in consolidation. *Learn Mem* **13**, 426-430 (2006).
177. Costa, B. et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. *Br J Pharmacol* (2006).
178. Hamamoto, D. T., Giridharagopalan, S. & Simone, D. A. Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. *Eur J Pharmacol* **5** (2006).
179. Jayamanne, A. et al. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. *Br J Pharmacol* **147**, 281-288 (2006).
180. Kage, K. L. et al. A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase. *J Neurosci Methods* (2006).
181. Ware, M. A., Adams, H. & Guy, G. W. The medicinal use of cannabis in the UK: results of a nationwide survey. *Int J Clin Pract* **59**, 291-295 (2005).
182. Fowler, C. J. Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors. *Curr Drug Targets CNS Neurol Disord* **4**, 685-696 (2005).
183. Djulus, J., Moretti, M. & Koren, G. Marijuana use and breastfeeding. *Can Fam Physician* **51**, 349-350 (2005).
184. Mitchell, V. A., Aslan, S., Safaei, R. & Vaughan, C. W. Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain. *Neurosci Lett* **382**, 231-235 (2005).
185. Dyson, A. et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. *Pain* **116**, 129-137 (2005).
186. Burstein, S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. *AAPS J* **7**, E143-E148 (2005).
187. Killestein, J., Bet, P. M., van Loenen, A. C. & Polman, C. H. [Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]. *Ned Tijdschr Geneeskde* **148**, 2374-2378 (2004).
188. Rukwied, R., Gauter, B., Schley, M. & Konrad, C. [Cannabinoids-signal transduction and mode of action.]. *Schmerz* (2004).
189. Deusch, E., Kress, H. G., Kraft, B. & Kozek-Langenecker, S. A. The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. *Anesth Analg* **99**, 1127-30, table of contents (2004).
190. Ulugol, A., Karadag, H. C., Ipci, Y., Tamer, M. & Dokmeci, I. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. *Neurosci Lett* **371**, 167-170 (2004).
191. Cichewicz, D. L. Synergistic interactions between cannabinoid and opioid analgesics. *Life Sci* **74**, 1317-1324 (2004).
192. Manzanares, J., Uriguen, L., Rubio, G. & Palomo, T. Role of endocannabinoid system in mental diseases. *Neurotox Res* **6**, 213-224 (2004).
193. Costa, B. et al. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. *Br J Pharmacol* **141**, 4-8 (2004).
194. De Vry, J., Kuhl, E., Franken-Kunkel, P. & Eckel, G. Pharmacological

- characterization of the chronic constriction injury model of neuropathic pain. *Eur J Pharmacol* **491**, 137-148 (2004).
195. Smith, P. F. Medicinal cannabis extracts for the treatment of multiple sclerosis. *Curr Opin Investig Drugs* **5**, 727-730 (2004).
 196. Yesilyurt, O. & Dogrul, A. Lack of cross-tolerance to the antinociceptive effects of systemic and topical cannabinoids in morphine-tolerant mice. *Neurosci Lett* **371**, 122-127 (2004).
 197. Notcutt, W. et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. *Anaesthesia* **59**, 440-452 (2004).
 198. Wood, S. Evidence for using cannabis and cannabinoids to manage pain. *Nurs Times* **100**, 38-40 (2004).
 199. Attal, N. et al. Are oral cannabinoids safe and effective in refractory neuropathic pain? *Eur J Pain* **8**, 173-177 (2004).
 200. Burstein, S. H., Karst, M., Schneider, U. & Zurier, R. B. Ajulemic acid: A novel cannabinoid produces analgesia without a "high". *Life Sci* **75**, 1513-1522 (2004).
 201. Soria, G. et al. Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. *Eur J Neurosci* **20**, 2203-2213 (2004).
 202. Soyka, M. [Cannabinoids and mental health]. *Schmerz* **17**, 268-273 (2003).
 203. Radbruch, L. & Nauck, F. [A review of side effects and complications with cannabinoid treatment]. *Schmerz* **17**, 274-279 (2003).
 204. Lim, G., Sung, B., Ji, R. R. & Mao, J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. *Pain* **105**, 275-283 (2003).
 205. Rudich, Z., Stinson, J., Jeavons, M. & Brown, S. C. Treatment of chronic intractable neuropathic pain with dronabinol: case report of two adolescents. *Pain Res Manag* **8**, 221-224 (2003).
 206. Hall, W. & Degenhardt, L. Medical marijuana initiatives : are they justified? How successful are they likely to be? *CNS Drugs* **17**, 689-697 (2003).
 207. Helyes, Z. et al. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. *Life Sci* **73**, 2345-2353 (2003).
 208. Zhang, J. et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. *Eur J Neurosci* **17**, 2750-2754 (2003).
 209. Grotenhermen, F. & Muller-Vahl, K. IACM 2nd Conference on Cannabinoids in Medicine. *Expert Opin Pharmacother* **4**, 2367-2371 (2003).
 210. Nitu, A. N., Wallihan, R., Skljarevski, V. & Ramadan, N. M. Emerging trends in the pharmacotherapy of chronic pain. *Expert Opin Investig Drugs* **12**, 545-559 (2003).
 211. Malan, T. P. J. et al. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? *Curr Opin Pharmacol* **3**, 62-67 (2003).
 212. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. *Drugs R D* **4**, 306-309 (2003).
 213. Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E. & Clark, A. J. Cannabis use for chronic non-cancer pain: results of a prospective survey. *Pain* **102**, 211-216 (2003).

214. Iversen, L. Cannabis and the brain. *Brain* **126**, 1252-1270 (2003).
215. Karst, M. et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. *JAMA* **290**, 1757-1762 (2003).
216. Krenn, H., Daha, L. K., Oczenski, W. & Fitzgerald, R. D. A case of cannabinoid rotation in a young woman with chronic cystitis. *J Pain Symptom Manage* **25**, 3-4 (2003).
217. Kehl, L. J. et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. *Pain* **103**, 175-186 (2003).
218. Heppelmann, B. [Why gamble with pain and analgesia? New approaches in central analgesia]. *Pharm Unserer Zeit* **31**, 96-100 (2002).
219. Clermont-Gnamien, S. et al. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain]. *Presse Med* **31**, 1840-1845 (2002).
220. Lambert, D. M., Vandevoorde, S., Jonsson, K. O. & Fowler, C. J. The palmitoylethanolamide family: a new class of anti-inflammatory agents? *Curr Med Chem* **9**, 663-674 (2002).
221. MacPherson, R. D. New directions in pain management. *Drugs Today (Barc)* **38**, 135-145 (2002).
222. Castane, A. et al. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. *Neuropharmacology* **43**, 857-867 (2002).
223. Fernandez-Ruiz, J., Lastres-Becker, I., Cabranes, A., Gonzalez, S. & Ramos, J. A. Endocannabinoids and basal ganglia functionality. *Prostaglandins Leukot Essent Fatty Acids* **66**, 257-267 (2002).
224. Anikwue, R., Huffman, J. W., Martin, Z. L. & Welch, S. P. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. *J Pharmacol Exp Ther* **303**, 340-346 (2002).
225. Sidney, S. Cardiovascular consequences of marijuana use. *J Clin Pharmacol* **42**, 64S-70S (2002).
226. Hama, A. T. Capsaicin-sensitive primary afferents mediate responses to cold in rats with a peripheral mononeuropathy. *Neuroreport* **13**, 461-464 (2002).
227. Ware, M. A., Gamsa, A., Persson, J. & Fitzcharles, M. A. Cannabis for chronic pain: case series and implications for clinicians. *Pain Res Manag* **7**, 95-99 (2002).
228. Smith, P. F. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. *Curr Opin Investig Drugs* **3**, 859-864 (2002).
229. Pertwee, R. G. Cannabinoids and multiple sclerosis. *Pharmacol Ther* **95**, 165-174 (2002).
230. Elsner, F., Radbruch, L. & Sabatowski, R. [Tetrahydrocannabinol for treatment of chronic pain]. *Schmerz* **15**, 200-204 (2001).
231. Gill, A. & Williams, A. C. Preliminary study of chronic pain patients' concerns about cannabinoids as analgesics. *Clin J Pain* **17**, 245-248 (2001).
232. Palla, S. Meeting review: Pain in Europe: Third Congress of the European Federation of IASP Chapters. Nice, September 26-29, 2000. *J Orofac Pain* **15**, 174-176 (2001).
233. Kalant, H. Medicinal use of cannabis: history and current status. *Pain Res Manag* **6**, 80-91 (2001).
234. Monhemius, R., Azami, J., Green, D. L. & Roberts, M. H. CB1 receptor mediated

- analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. *Brain Res* **908**, 67-74 (2001).
235. Klein, T. W., Newton, C. A. & Friedman, H. Cannabinoids and the immune system. *Pain Res Manag* **6**, 95-101 (2001).
236. Pertwee, R. G. Cannabinoid receptors and pain. *Prog Neurobiol* **63**, 569-611 (2001).
237. Siegling, A., Hofmann, H. A., Denzer, D., Mauler, F. & De Vry, J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. *Eur J Pharmacol* **415**, R5-R7 (2001).
238. Campbell, F. A. et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. *BMJ* **323**, 13-16 (2001).
239. Zimmer, A. et al. Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. *J Neurosci* **21**, 9499-9505 (2001).
240. Attal, N. & Bouhassira, D. [Recent pharmacologic approaches to pain]. *Ann Pharm Fr* **58**, 121-134 (2000).
241. De Petrocellis, L., Melck, D., Bisogno, T. & Di Marzo, V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. *Chem Phys Lipids* **108**, 191-209 (2000).
242. Vaughan, C. W. & Christie, M. J. An analgesic role for cannabinoids. *Med J Aust* **173**, 270-272 (2000).
243. Fishbain, D. A., Cutler, R. B., Rosomoff, H. L. & Rosomoff, R. S. Validity of self-reported drug use in chronic pain patients. *Clin J Pain* **15**, 184-191 (1999).
244. Walker, J. M. et al. The neurobiology of cannabinoid analgesia. *Life Sci* **65**, 665-673 (1999).
245. Pertwee, R. G. Cannabis and cannabinoids: pharmacology and rationale for clinical use. *Forsch Komplementarmed* **6 Suppl 3**, 12-15 (1999).
246. Strangman, N. M. & Walker, J. M. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. *J Neurophysiol* **82**, 472-477 (1999).
247. Chaperon, F. & Thiebot, M. H. Behavioral effects of cannabinoid agents in animals. *Crit Rev Neurobiol* **13**, 243-281 (1999).
248. Dajani, E. Z. et al. 1',1'-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. *J Pharmacol Exp Ther* **291**, 31-38 (1999).
249. Richardson, J. D., Aanonsen, L. & Hargreaves, K. M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. *J Neurosci* **18**, 451-457 (1998).
250. Smith, F. L., Fujimori, K., Lowe, J. & Welch, S. P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. *Pharmacol Biochem Behav* **60**, 183-191 (1998).
251. Hutcheson, D. M. et al. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. *Br J Pharmacol* **125**, 1567-1577 (1998).
252. Taylor, H. G. Analysis of the medical use of marijuana and its societal implications. *J Am Pharm Assoc (Wash)* **38**, 220-227 (1998).
253. Consroe, P., Musty, R., Rein, J., Tillery, W. & Pertwee, R. The perceived effects of smoked cannabis on patients with multiple sclerosis. *Eur Neurol* **38**, 44-48 (1997).

254. Herzberg, U., Eliav, E., Bennett, G. J. & Kopin, I. J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. *Neurosci Lett* **221**, 157-160 (1997).
255. Richardson, J. D., Aanonsen, L. & Hargreaves, K. M. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. *Eur J Pharmacol* **319**, R3-R4 (1997).
256. Holdcroft, A. et al. Pain relief with oral cannabinoids in familial Mediterranean fever. *Anaesthesia* **52**, 483-486 (1997).
257. Rubino, T., Tizzoni, L., Vigano, D., Massi, P. & Parolaro, D. Modulation of rat brain cannabinoid receptors after chronic morphine treatment. *Neuroreport* **8**, 3219-3223 (1997).
258. Rubino, T., Patrini, G., Parenti, M., Massi, P. & Parolaro, D. Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. *Brain Res Mol Brain Res* **44**, 191-197 (1997).
259. Thorat, S. N. & Bhargava, H. N. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. *Eur J Pharmacol* **260**, 5-13 (1994).
260. Hanks, G. W. Psychotropic drugs. *Postgrad Med J* **60**, 881-885 (1984).
261. Novelli, G. P., Peduto, V. A., Bertol, E., Mari, F. & Pieraccioli, E. Analgesic interaction between nitrous oxide and delta-9-tetrahydrocannabinol in the rat. *Br J Anaesth* **55**, 997-1000 (1983).
262. Jones, R. T., Benowitz, N. L. & Herning, R. I. Clinical relevance of cannabis tolerance and dependence. *J Clin Pharmacol* **21**, 143S-152S (1981).
263. Berdiaev, S. I. & Pokryshkin, V. I. [Changes in the defensive and alimentary behavior of rabbits following multiple hashish administrations to different brain regions]. *Biull Eksp Biol Med* **90**, 300-303 (1980).
264. Rosell, S. [Pharmacology of cannabinoids]. *Lakartidningen* **73**, 3864-3866 (1976).